Excited to announce our latest publication in the Journal of the American Academy of Dermatology: “Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry”. In this prospective and multicenter study, we investigated the long-term effectiveness and safety of dupilumab in 1223 patients with moderate-to-severe atopic dermatitis, including 1108 adults and 115 pediatric patients, enrolled in the BioDay registry and treated with dupilumab between October 2017-2022. We observed that after ≥1 year of treatment, mean scores for Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8-8.7, 3.5-4.2, and 2.9-3.1 in adults, respectively, whilst these scores ranged between 8.9-10.9, 4.4-6.4, and 3.0-3.7 in pediatric patients, respectively. At follow-up, overall work impairment decreased from 40.1% to 13.3-16.3% in adults. Furthermore, our findings reveal that patients with class I obesity and itch-dominant atopic dermatitis subset (defined as NRS-pruritus>4 and EASI≤21) generally had a less favorable treatment response. Of all patients, 66.8% reported at elast one adverse event, with conjunctivitis being the most common(33.7%). For those interested, the full article is available here: https://lnkd.in/gBev4Egc. I extend my sincere gratitude to all my co-authors and the participating patients for their invaluable contributions to this research.
Celeste Boesjes
8mo
It was great working together!
格罗宁根大学学生
8moCongratulations!